1. The principles of treatment for this disease are: to strive for ultra-early treatment, intravenous thrombolysis within 4.5 hours of onset as far as possible, and appropriate acute endovascular intervention within 6-8 hours of onset in hospitals with conditions; to determine individualized and holistic treatment plans, to use corresponding targeted treatment according to the patient’s own risk factors and degree of disease, and to combine the efforts of multiple departments such as neurosurgery, rehabilitation and nursing. To maximize the therapeutic effect and improve the prognosis, we will make efforts to achieve integrated treatment. The specific treatment measures are as follows: Mainly including the drug treatment to control blood pressure, blood sugar and blood lipid level. (1) Blood pressure control With reference to advanced age, basal blood pressure, usual medication and tolerability, the goal of blood pressure lowering should generally reach ≤140/90 mm Hg, and ideally ≤130/80 mm Hg. Patients with diabetes combined with hypertension should strictly control blood pressure below 130/80 mm Hg, and blood pressure lowering drugs should be angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and other drugs to reduce cardiovascular events. The benefits of these drugs in reducing cardiovascular and cerebrovascular events are obvious. The following points should be noted with regard to blood pressure control in the acute phase: ① In preparation for thrombolysis, systolic blood pressure should be <180 mmhg and diastolic blood pressure <100 mmhg. ② Patients with elevated blood pressure within 24 h after ischemic stroke should be managed with caution. Tension and anxiety, pain, nausea and vomiting, and increased intracranial pressure should be managed first. Persistently elevated blood pressure with systolic blood pressure ≥ 200 mmhg or diastolic blood pressure ≥ 110 mmhg, or with severe cardiac insufficiency, aortic coarctation, or hypertensive encephalopathy, may be treated with cautious antihypertensive therapy and closely monitored for blood pressure changes. Short-acting drugs (e.g. labetalol, nicardipine) may be administered intravenously if necessary, and a microinfusion pump should preferably be applied to avoid dropping the blood pressure too low. (3) If you have a history of hypertension and are taking antihypertensive drugs, you can resume the use of antihypertensive drugs 24h after stroke if your condition is stable. ④Patients with post-stroke hypotension should actively seek and deal with the cause, and if necessary, use measures to increase blood pressure by expansion. (2) Blood glucose control Fasting blood glucose should be <7mmol/L (126mg/dl), and the target goal of diabetic blood glucose control is HbAlc<6. 5%, and if necessary, high blood glucose can be controlled by controlling diet, oral hypoglycemic drugs or using insulin. The following two points should be noted in the acute phase of blood glucose control: ① Insulin treatment can be given when blood glucose exceeds 11.1 mmol/L. ①If blood glucose is less than 2.8 mmol/L, it can be treated with 10%-20% glucose orally or by injection. (3) Lipid-regulating therapy Several recommendations for lipid-regulating pharmacotherapy in patients with cerebral infarction are as follows: ① Patients with ischemic stroke and TIA with elevated cholesterol levels should undergo lifestyle intervention and pharmacotherapy. Statins are recommended, with the goal of reducing LDL-C levels to below 2.59 mmol/L or achieving a 30-40% reduction in LDL-C. ② Patients with ischemic stroke and TIA with multiple risk factors (coronary artery disease, diabetes mellitus, unabated smoking, metabolic syndrome, cerebral atherosclerotic lesions without definite evidence of vulnerable plaque or arterial-derived embolism or one of the peripheral arterial diseases) who have LDL-C > 2.07 mmol/L should reduce LDL-C to less than 2. 07 mmol/L or achieve an LDL-C down by >40%. (iii) Early initiation of intensive statin therapy is recommended for patients with ischemic stroke and TIA with evidence of atherosclerotic vulnerable plaque or arterial-derived embolism in large intracranial and extracranial arteries, with a recommended target LDL-C <2.07 mmol/L or resulting in an LDL-C reduction >40%. ④ Long-term statin use is generally safe. Before and during statin therapy, clinical symptoms such as myalgia and changes in liver enzymes (glutamate and aspartate aminotransferase) and muscle enzymes (creatine kinase) should be monitored regularly. If elderly patients are combined with important organ insufficiency or multiple drugs are used in combination, attention should be paid to the reasonable combination and monitoring of adverse reactions. ⑤ For people with a history of cerebral hemorrhage or at high risk of cerebral hemorrhage, the risks and benefits should be weighed and caution is recommended in the use of statins. 3.Special treatment mainly includes thrombolytic therapy, antiplatelet aggregation and anticoagulant drug therapy, neuroprotective agents, endovascular intervention and surgical treatment, etc. (1) Thrombolytic therapy, which requires hospital infusion treatment. (2) Anti-platelet aggregation therapy, for patients with ischemic stroke who do not meet the indications for thrombolysis and have no contraindications should be given oral aspirin 150-300 mg/d as soon as possible after the onset of stroke; after the acute phase, it can be changed to a prophylactic dose of 50-150 mg/d; for those who cannot tolerate aspirin, antiplatelet therapy such as clopidogrel can be considered. (3) Anticoagulation therapy, mainly including heparin, low molecular heparin and warfarin. (4) Neuroprotective agents, such as free radical scavengers, voltage-gated calcium channel blockers, excitatory amino acid receptor blockers, etc., can be tried in the treatment of patients with acute cerebral infarction. 4. Prevention and treatment of complications Various complications are likely to occur during the acute and recovery periods of cerebral infarction, among which aspiration pneumonia, decubitus ulcer, urinary tract infection, deep vein thrombosis and pulmonary embolism of the lower extremities, malnutrition due to dysphagia, etc. can significantly increase the risk of poor prognosis. Therefore, effective prevention and close care of these complications is also a key aspect in the process of standardized treatment of cerebral infarction. 5. Rehabilitation therapy and psychological adjustment therapy Individualized long-term rehabilitation training programs for patients with cerebral infarction should be started as early as possible, and reasonable rehabilitation measures should be adopted according to local conditions. Some research results suggest that 6 months after the onset of cerebral infarction is the ‘golden period’ for neurological function recovery, and the effective rehabilitation of language function can even last for several years. At the same time, psychological and social adjuvant treatment for patients with cerebral infarction can also help to reduce the disability rate, improve the quality of life and promote their early reintegration into society. 6.Prognosis of the disease The death rate of the disease is about 10%, and the disability rate can be more than 50%. The recurrence rate of survivors is as high as 40%, and recurrence of cerebral infarction can seriously weaken the daily life and social functions of patients, and can significantly increase the mortality rate.